SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-024618
Filing Date
2022-02-01
Accepted
2022-02-01 16:23:55
Documents
14
Period of Report
2022-01-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d198795d8k.htm   iXBRL 8-K 28135
2 EX-99.1 d198795dex991.htm EX-99.1 11275
6 GRAPHIC g198795dsp004.jpg GRAPHIC 7172
  Complete submission text file 0001193125-22-024618.txt   181806

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20220130.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20220130_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20220130_pre.xml EX-101.PRE 11724
8 EXTRACTED XBRL INSTANCE DOCUMENT d198795d8k_htm.xml XML 3465
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 22579219
SIC: 2836 Biological Products, (No Diagnostic Substances)